Topovale
Based on 1 Customer Validation
Topovale (ARC 111) is a topoisomerase I inhbitor. Topovale is an antitumor agent, and shows low nM cytotoxicity against a panel of cancer cells. Topovale induces reversible topoisomerase I (TOP1) cleavage complexes in tumor cells.
For research use only. We do not sell to patients.
- Purity : 99.94%
- CAS No.: 500214-53-9
- Formula: C23H23N3O5
- Molecular Weight:421.45
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
All Topoisomerase Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
Topoisomerase I |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | GI50 |
0.177 μM
Compound: ARC-111
|
Growth inhibition of human HCT-116 cells by Cell-titer96 assay
Growth inhibition of human HCT-116 cells by Cell-titer96 assay
|
[PMID: 33492141] |
| KB | IC50 |
0.005 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1
Concentration required to inhibit cell proliferation in KBV-1 tumor cell line; overexpress MDR1
|
[PMID: 15482929] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1
|
Cytotoxicity against human KB3-1 cells by MTT method
Cytotoxicity against human KB3-1 cells by MTT method
|
[PMID: 18771930] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against human KB3-1 cells after 4 days by MTT assay
Cytotoxicity against human KB3-1 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against human KB3-1 cells after MTT assay
Cytotoxicity against human KB3-1 cells after MTT assay
|
[PMID: 18829334] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against human KB3-1 cells after 4 days after MTT assay
Cytotoxicity against human KB3-1 cells after 4 days after MTT assay
|
[PMID: 19299037] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against human KB3-1 cells after 4 days by MTT method
Cytotoxicity against human KB3-1 cells after 4 days by MTT method
|
[PMID: 19303306] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in KB3-1 tumor cell line
Concentration required to inhibit cell proliferation in KB3-1 tumor cell line
|
[PMID: 15482929] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 3
|
Inhibitory concentration against KB/V-1 cells overexpress MDR1
Inhibitory concentration against KB/V-1 cells overexpress MDR1
|
[PMID: 15689163] |
| KB 3-1 | IC50 |
0.005 μM
Compound: 3
|
Inhibitory concentration against KB3-1 cell line was determined
Inhibitory concentration against KB3-1 cell line was determined
|
[PMID: 15689163] |
| KB 3-1 | IC50 |
0.006 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP
Concentration required to inhibit cell proliferation in KBH5.0 tumor cell line; overexpress BCRP
|
[PMID: 15482929] |
| KB-V1 | IC50 |
0.002 μM
Compound: 1, ARC-111
|
Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method
Cytotoxicity against MDR1 overexpressing human KBV1 cells after 4 days by MTT method
|
[PMID: 19303306] |
| KB-V1 | IC50 |
0.005 μM
Compound: 1
|
Cytotoxicity against human KBV1 cells by MTT method
Cytotoxicity against human KBV1 cells by MTT method
|
[PMID: 18771930] |
| KB-V1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay
Cytotoxicity against multidrug resistant human KBV-1 cells overexpressing MDR1 after MTT assay
|
[PMID: 18829334] |
| KB-V1 | IC50 |
0.005 μM
Compound: 1, ARC-111
|
Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 after 4 days by MTT assay
Cytotoxicity against multidrug resistant human KBV1 cells overexpressing MDR1 after 4 days by MTT assay
|
[PMID: 19299037] |
| KB-V1 | IC50 |
0.015 μM
Compound: 1, ARC-111
|
Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay
Cytotoxicity against human multidrug resistant MDR1 overexpressing human KBV1 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| P388 | IC50 |
0.001 μM
Compound: 1
|
Cytotoxicity against mouse P388 cells by MTT method
Cytotoxicity against mouse P388 cells by MTT method
|
[PMID: 18771930] |
| P388 | IC50 |
0.001 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| P388 | IC50 |
0.001 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse P388 cells after MTT assay
Cytotoxicity against mouse P388 cells after MTT assay
|
[PMID: 18829334] |
| P388 | IC50 |
0.001 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
Cytotoxicity against mouse P388 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| P388 | IC50 |
0.001 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse P388 cells after 4 days by MTT method
Cytotoxicity against mouse P388 cells after 4 days by MTT method
|
[PMID: 19303306] |
| P388 | IC50 |
0.001 nM
Compound: 1, ARC-111
|
Cytotoxicity against human P388 cells
Cytotoxicity against human P388 cells
|
[PMID: 18511275] |
| P388 | IC50 |
0.001 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in P388 tumor cell line
Concentration required to inhibit cell proliferation in P388 tumor cell line
|
[PMID: 15482929] |
| P388 | IC50 |
0.001 μM
Compound: 3
|
Inhibitory concentration against P388 cell line in mouse leukemia was determine
Inhibitory concentration against P388 cell line in mouse leukemia was determine
|
[PMID: 15689163] |
| P388 | IC50 |
0.23 μM
Compound: 1
|
Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
Cytotoxicity against camptothecin-resistant mouse P388 cells by MTT method
|
[PMID: 18771930] |
| P388 | IC50 |
0.23 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay
Cytotoxicity against mouse CPT45-resistant topoisomerase 1-deficient P388 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| P388 | IC50 |
0.23 μM
Compound: 1, ARC-111
|
Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method
Cytotoxicity against camptothecin-resistant mouse P388 cells after 4 days by MTT method
|
[PMID: 19303306] |
| P388 | IC50 |
0.23 μM
Compound: 3
|
Inhibitory concentration against camptothecin-resistant variant of P388 cell line was determined
Inhibitory concentration against camptothecin-resistant variant of P388 cell line was determined
|
[PMID: 15689163] |
| P388CPT45 | IC50 |
0.23 μM
Compound: 1, ARC-111
|
Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
Cytotoxicity against camptothecin-resistant and TOP1 deficient mouse P388/CPT45 cells after MTT assay
|
[PMID: 18829334] |
| P388CPT45 | IC50 |
0.23 μM
Compound: 1, ARC-111
|
Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay
Cytotoxicity against mouse P388/CPT45 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1
|
Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
Cytotoxic activity against human lymphoblast tumor cell line RPMI8402 after 4 days of treatment
|
[PMID: 12747798] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1
|
Cytotoxicity against human RPMI8402 cells by MTT method
Cytotoxicity against human RPMI8402 cells by MTT method
|
[PMID: 18771930] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1, ARC-111
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
|
[PMID: 18676151] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1, ARC-111
|
Cytotoxicity against human RPMI8402 cells after MTT assay
Cytotoxicity against human RPMI8402 cells after MTT assay
|
[PMID: 18829334] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1, ARC-111
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
Cytotoxicity against human RPMI8402 cells after 4 days by MTT assay
|
[PMID: 19299037] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1, ARC-111
|
Cytotoxicity against human RPMI8402 cells after 4 days by MTT method
Cytotoxicity against human RPMI8402 cells after 4 days by MTT method
|
[PMID: 19303306] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in RPM18402 tumor cell line
Concentration required to inhibit cell proliferation in RPM18402 tumor cell line
|
[PMID: 15482929] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 3
|
Inhibitory concentration against lymphoblast RPMI 8402 cell line was determined
Inhibitory concentration against lymphoblast RPMI 8402 cell line was determined
|
[PMID: 15689163] |
| RPMI 8402 | IC50 |
0.002 μM
Compound: 3a
|
Cytotoxicity against human lymphoblast tumor cell line RPM18402
Cytotoxicity against human lymphoblast tumor cell line RPM18402
|
[PMID: 12392745] |
| RPMI 8402 | IC50 |
0.9 μM
Compound: 3a
|
Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1
Cytotoxicity using camptothecin-resistant variant of RPM18402 (CPT-K5) possessing functional, but mutant TOP-1
|
[PMID: 12392745] |
| RPMI 8402 | IC50 |
0.9 μM
Compound: 1
|
Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant
Concentration required to inhibit cell proliferation in CPT-K5 tumor cell line; camptothecin resistant
|
[PMID: 15482929] |
| RPMI 8402 | IC50 |
0.9 μM
Compound: 3
|
Cytotoxicity against camptothecin-resistant RPMI 8402
Cytotoxicity against camptothecin-resistant RPMI 8402
|
[PMID: 15689163] |
Chemical Information
-
CAS No. 500214-53-9
-
Appearance Solid
-
Molecular Weight 421.45
-
Formula C23H23N3O5
-
Color White to off-white
-
SMILES
COC1=C(C=C(C2=C1)C(N(C3=C2C=NC4=C3C=C5OCOC5=C4)CCN(C)C)=O)OC
-
Synonyms
ARC 111
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 4.03 mg/mL (9.56 mM; ultrasonic and adjust pH to 2 with TFA; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3728 mL | 11.8638 mL | 23.7276 mL | 59.3190 mL |
| 5 mM | 0.4746 mL | 2.3728 mL | 4.7455 mL | 11.8638 mL |